23rd Annual University of Chicago Developmental Therapeutics Symposium

23rd Annual University of Chicago Developmental Therapeutics Symposium is organized by The University of Chicago - Center for Continuing Medical Education and will be held on Apr 20, 2018 at Gleacher Center, Chicago, Illinois, United States of America.

The target audience for this medical event is physicians and other healthcare professionals currently involved in the diagnosis, screening, and treatment of cancer patients. This CME Conference has been approved for a maximum of 5 AMA PRA Category 1 Credits.

Course Description:
The goals of this activity are to help consortium members assimilate requirements of new studies, review synthesized data from completed studies, discuss the novel investigational agents available from the National Cancer Institute and other sponsors, describe the rational for and results of studies that include new targeted agents for the treatment of patients with advanced and rare disease. This knowledge will enable them to make new treatments available to cancer patients, provide support for current and future oncology clinical trials, and become stronger leaders in the area of oncology research. This program will convey information on how to implement precision medicine in oncology, leading to better outcomes for patients suffering from cancer.

Conference Objectives are :
At the conclusion of this activity, participants will be able to:
• State the effects of the use of novel experimental agents from the National Cancer Institute and other sponsors;
• Cite the relevant pharmacology and biologic effects of novel anti-cancer agents through the use of blood and tissue samples as well as standard and novel imaging approaches;
• Assess patient suitability for participation in available and upcoming cancer clinical trials and projects;
• Discuss advances in the use of chemotherapy and other targeted therapies for cancer;
• Describe the rational for and results of studies that include new targeted agents for the treatment of patients with advanced and rare disease;
• Summarize how updated regulatory and data operations information can support clinical trial conduct as administrative systems evolve.

Additional details will be posted as soon as they are available.